Skip to Content

Dicloxacillin

Medically reviewed by Drugs.com. Last updated on Jun 18, 2020.

Pronunciation

(dye kloks a SIL in)

Index Terms

  • Dicloxacillin Sodium

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 250 mg, 500 mg

Pharmacologic Category

  • Antibiotic, Penicillin

Pharmacology

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Absorption

Rapid and incomplete; reduced by food

Distribution

Vd: 5.99 L; increased in patients with ESRD on IHD (Nauta 1976); CSF penetration is low

Excretion

Feces; urine (as unchanged drug)

Neonates: Prolonged

CF patients: More rapid excretion than healthy patients (Jusko 1975)

Time to Peak

Serum: 1 to 1.5 hours

Half-Life Elimination

~0.7 hours; prolonged with renal impairment (Nauta 1976)

Protein Binding

95% to 99%

Use: Labeled Indications

Staphylococcal infections: Treatment of infections caused by penicillinase-producing staphylococci.

Off Label Uses

Bite wounds (animal)

Based on the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of skin and soft tissue infections (SSTI), dicloxacillin, in combination with penicillin, is an effective and recommended option for treatment of animal bites.

Impetigo

Based on the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of skin and soft tissue infections (SSTI), dicloxacillin is an effective and recommended agent for treatment of impetigo [IDSA [Stevens 2014].

Contraindications

Hypersensitivity to dicloxacillin, other penicillins, or any component of the formulation

Dosing: Adult

Staphylococcal infections: Oral: 125 to 250 mg every 6 hours.

Bite wounds (animal) (off-label use): Oral: 500 mg 4 times daily; in combination with penicillin (IDSA [Stevens 2014]).

Impetigo (off-label use): Oral: 250 mg 4 times daily for 7 days, depending on response (IDSA [Stevens 2014]).

Prosthetic joint infection: Chronic suppression therapy: Staphylococci (oxacillin-susceptible) (off-label dose): Oral: 500 mg every 6 to 8 hours (Osmon 2013).

Skin and soft tissue infection due to MSSA (off-label dose): Oral: 500 mg every 6 hours for 7 to 14 days (IDSA [Stevens 2014]).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

General dosing, susceptible infection (Bradley 2016; Red Book [AAP 2015]): Infants, Children, and Adolescents:

Mild to moderate infection: Oral: 12 to 25 mg/kg/day divided every 6 hours; maximum dose: 250 mg/dose

Severe infection (step-down therapy of bone and joint infection): Oral: 100 mg/kg/day divided every 6 hours; maximum dose: 500 mg/dose

Skin and soft tissue infection, methicillin-susceptible Staphylococcus aureus (MSSA): Infants, Children, and Adolescents: Oral: 25 to 50 mg/kg/day divided every 6 hours; maximum dose: 500 mg/dose (IDSA [Stevens 2014])

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Administration

Oral: Administer 1 hour before or 2 hours after meals with at least 120 mL of water. Administer around-the-clock to promote less variation in peak and trough serum levels. Should not be administered in the supine position or immediately before going to bed.

Storage

Store at 20°C to 25°C (68°F to 77°F).

Drug Interactions

Acemetacin: May increase the serum concentration of Penicillins. Monitor therapy

Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. Monitor therapy

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy

Brivaracetam: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Brivaracetam. Monitor therapy

Carisoprodol: CYP2C19 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Carisoprodol. CYP2C19 Inducers (Moderate) may decrease the serum concentration of Carisoprodol. Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Avoid combination

CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. Monitor therapy

DiazePAM: CYP2C19 Inducers (Moderate) may decrease the serum concentration of DiazePAM. Monitor therapy

Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. Monitor therapy

Etravirine: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Etravirine. Monitor therapy

Fosphenytoin-Phenytoin: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Fosphenytoin-Phenytoin. Monitor therapy

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy

Methotrexate: Penicillins may increase the serum concentration of Methotrexate. Monitor therapy

Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. Monitor therapy

Nelfinavir: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Nelfinavir. Monitor therapy

NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. Monitor therapy

Omeprazole: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Omeprazole. Monitor therapy

Ospemifene: Dicloxacillin may decrease the serum concentration of Ospemifene. Monitor therapy

Probenecid: May increase the serum concentration of Penicillins. Monitor therapy

Selpercatinib: CYP3A4 Inducers (Weak) may decrease the serum concentration of Selpercatinib. Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification

Tacrolimus (Systemic): CYP3A4 Inducers (Weak) may decrease the serum concentration of Tacrolimus (Systemic). Monitor therapy

Tetracyclines: May diminish the therapeutic effect of Penicillins. Monitor therapy

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Consider therapy modification

Ubrogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Ubrogepant. Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer. Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Dicloxacillin may diminish the anticoagulant effect of Vitamin K Antagonists. Monitor therapy

Voriconazole: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Voriconazole. Monitor therapy

Test Interactions

False-positive urine and serum proteins; false-positive in uric acid, urinary steroids; may interfere with urinary glucose tests using cupric sulfate (Benedict's solution, Clinitest®); may inactivate aminoglycosides in vitro

Adverse Reactions

Frequency not defined.

1% to 10%: Gastrointestinal: Abdominal pain diarrhea, nausea

<1%, postmarketing, and/or case reports: Agranulocytosis, anemia, eosinophilia, fever, hematuria, hemolytic anemia, hepatotoxicity, hypersensitivity reaction, increased blood urea nitrogen, increased liver enzymes (transient), increased serum creatinine, interstitial nephritis, leukopenia, neutropenia, prolonged prothrombin time, pseudomembranous colitis, seizure (with extremely high doses and/or renal failure), serum sickness-like reaction, skin rash (maculopapular rash to exfoliative dermatitis), thrombocytopenia, vaginitis, vomiting

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have been reported in patients on penicillin therapy. Initiate therapy only after a comprehensive drug and allergy history; use with caution in patients with a history of significant allergies and/or asthma. Discontinue use and institute appropriate therapy if a hypersensitivity reaction occurs.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Special populations:

• Neonates: Use with caution in neonates; elimination of drug is slow.

Monitoring Parameters

Baseline and periodic CBC with differential; periodic BUN, serum creatinine, AST and ALT (especially with prolonged therapy); prothrombin time if patient concurrently on warfarin; signs of anaphylaxis during first dose

Pregnancy Risk Factor

B

Pregnancy Considerations

Dicloxacillin crosses the placenta (Depp 1970; MacAulay 1968; Seiga 1974).

Penicillin class antibiotics cross the placenta in varying degrees. Dicloxacillin is highly protein bound, which may influence fetal exposure (Nau 1987).

As a class, penicillin antibiotics are widely used in pregnant women. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Lamont 2014; Muanda 2017a; Muanda 2017b).

Patient Education

What is this drug used for?

• It is used to treat bacterial infections.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Diarrhea

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Shortness of breath

• Severe nausea

• Vomiting

• Mouth irritation

• Tongue discoloration

• Bruising

• Bleeding

• Sore throat

• Muscle pain

• Joint pain

• Joint swelling

• Severe dizziness

• Passing out

Clostridioides (formerly Clostridium) difficile-associated diarrhea like abdominal pain or cramps, severe diarrhea or watery stools, or bloody stools.

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.